DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 50608/S-041
NDA 50608/S-042

SUPPLEMENT APPROVAL

Pfizer, Inc.
Attention: Shai Srulovich
Senior Manager, Worldwide Regulatory Strategy
235 East 42nd Street
New York, NY 10017

Dear Mr. Srulovich:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received September 13, 2013 (S-041) and December 19, 2013 (S-042), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Unasyn (ampicillin sodium/sulbactam sodium) Injection.

We acknowledge receipt of your amendments dated March 3 (S-042), June 5, July 18, September 30 and October 24, 2014.

These "Changes Being Effected" supplemental new drug applications proposed to add cholestatic hepatitis and cholestasis (S-041) and phlebitis (S-042) to the **ADVERSE REACTIONS** section of the package insert.

In addition, the following sections have been revised:

- **CONTRAINDICATIONS:** Addition of a contraindication for use in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with Unasyn
- **WARNINGS:** Addition of a new section on hepatotoxicity
- **DIRECTIONS FOR USE** (pharmacy bulk package)

Minor editorial changes have also been made to the package insert and the References have been updated.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susmita Samanta, Safety Regulatory Project Manager, at (301) 796-0803.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, M.D., M.P.H.
Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
11/17/2014